For instance, several anti-PD-1 and anti-PD-L1 monoclonal blocking antibodies, including nivolumab, pembrolizumab, and atezolizumab, have been approved by Food and Drug Administration (FDA) of the United States as an effective drug for the treatment of malignant melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), Hodgkin lymphoma, squamous cell carcinoma of the head and neck, hepatocellular carcinoma, and others. This evidence concerns the gene CD274 and non-small cell lung carcinoma.